The following IPOs are expected to price this week:
Achaogen (AKAO), which is developing antibiotic treatments of multi-drug resistant infections, plans to raise $65 million by offering 5.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Achaogen would command a market value of $216 million. Achaogen, which was founded in 2002, booked $19 million in sales over the last 12 months. The South San Francisco, CA-based company plans to list on the NASDAQ under the symbol AKAO. Credit Suisse and Cowen & Company are the joint bookrunners on the deal.
Castlight Health (CSLT), which provides on-demand software that helps self-insured employers control healthcare costs, plans to raise $111 million by offering 11.1 million shares at a price range of $9.00 to $11.00. At the midpoint of the proposed range, Castlight Health would command a market value of $1.0 billion. Castlight Health, which was founded in 2008, booked $13 million in sales over the last 12 months. The San Francisco, CA-based company plans to list on the NYSE under the symbol CSLT. Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal.
Diamond S Shipping Group (DSG), a medium range product tanker operator backed by Wilbur Ross, plans to raise $210 million by offering 14.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Diamond S Shipping Group would command a market value of $710 million. Diamond S Shipping Group, which was founded in 2007, booked $178 million in sales over the last 12 months. The Greenwich, CT-based company plans to list on the NYSE under the symbol DSG. Jefferies & Co. and BofA Merrill Lynch are the joint bookrunners on the deal.
Dipexium Pharmaceuticals (DPRX), a late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections, plans to raise $30 million by offering 2.3 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Dipexium Pharmaceuticals would command a market value of $101 million. Dipexium Pharmaceuticals was founded in 2010. The New York, NY-based company plans to list on the NASDAQ under the symbol DPRX. Oppenheimer & Co. is the lead bookrunner on the deal.
Galmed Pharmaceuticals (GLMD), a clinical-stage biotech developing therapies for liver diseases and gallstones, plans to raise $31 million by offering 2.4 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Galmed Pharmaceuticals would command a market value of $148 million. Galmed Pharmaceuticals, which was founded in 2000, booked $0 million in sales over the last 12 months. The Tel Aviv, Israel-based company plans to list on the NASDAQ under the symbol GLMD. Maxim Group is the lead bookrunner on the deal.
Ignyta (RXDX), a clinical-stage biotech developing targeted cancer therapeutics, plans to raise $40 million by offering 4.4 million shares at a price range of $9.10 to $9.10. At the midpoint of the proposed range, Ignyta would command a market value of $172 million. Ignyta, which was founded in 2011, booked $0 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol RXDX. Leerink Partners is the lead bookrunner on the deal. (Please note: Currently trades on the OTC under the symbol RXDX.)
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there were 3 IPO pricings. Coupons.com (COUP), which distributes digital coupons for consumer packaged good companies, was the week's winner, ending up 88% from its IPO price.
